Amgen Inc

21 de jul. de 2026, 23:46 UTC

Amgen Inc shares are lower in after-market hours, reflecting a modest recovery from earlier losses. No specific news was identified to explain the movement.

20 de jul. de 2026, 19:56 UTC

Amgen Inc. shares are lower today, reflecting broader market trends amid geopolitical tensions and inflation concerns. The stock ranks fourth in the SCHD ETF.

17 de jul. de 2026, 20:02 UTC

Amgen Inc. shares are lower during Friday's session, despite a rise in the Michigan Consumer Sentiment Index to 54.4 in July.

16 de jul. de 2026, 18:02 UTC

Amgen Inc. shares are higher today, diverging from broader market declines amid rising crude oil prices and geopolitical tensions. No specific news was identified.

15 de jul. de 2026, 19:16 UTC

Amgen Inc shares are higher Wednesday, reflecting a positive market trend amid investor interest in biotechnology despite geopolitical tensions affecting the bond market.

14 de jul. de 2026, 19:16 UTC

Amgen Inc. shares are lower amid pressure from recent product recalls due to quality control issues, impacting its reputation and operational efficiency.

13 de jul. de 2026, 19:46 UTC

Shares lower today despite price target increases from Guggenheim, UBS.

10 de jul. de 2026, 23:16 UTC

Amgen Inc. shares are higher in after-market trading, remaining near the upper end of their one-month range amid rising U.S. Treasury yields.

9 de jul. de 2026, 23:01 UTC

Amgen Inc shares are trading lower in after-market hours, following unusual trading activity with no specific news identified to explain the decline.

8 de jul. de 2026, 23:21 UTC

Amgen Inc shares are lower in after-market hours, reflecting broader market declines amid geopolitical tensions and a significant drop in the DAX 30 Index.

7 de jul. de 2026, 19:06 UTC

Truist Securities raised Amgen's price target to $340, maintaining a Hold rating. Shares are advancing, reflecting positive sentiment and long-term value creation.

6 de jul. de 2026, 20:06 UTC

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2 de jul. de 2026, 23:06 UTC

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

1 de jul. de 2026, 19:11 UTC

Amgen Inc shares are lower amid social media discussions on AI's impact on drug discovery and client platform risk perceptions in the biopharma sector.

29 de jun. de 2026, 19:11 UTC

Amgen Inc shares are higher today, supported by a broader market rally and investor confidence from South Korea's $576 billion investment plan in technology.

26 de jun. de 2026, 23:06 UTC

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

25 de jun. de 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, continuing a recent positive trend with four consecutive sessions of gains. No specific news was identified.

24 de jun. de 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 de jun. de 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 de jun. de 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 de jun. de 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 de jun. de 2026, 19:53 UTC

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 de jun. de 2026, 19:22 UTC

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 de jun. de 2026, 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 de jun. de 2026, 19:51 UTC

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 de jun. de 2026, 23:06 UTC

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 de jun. de 2026, 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 de jun. de 2026, 19:56 UTC

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 de jun. de 2026, 20:06 UTC

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 de jun. de 2026, 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.